- Home
- RCKTW
as 05-10-2024 4:00pm EST
$.
+$.
+.%
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
| Founded: | N/A | Country: | United States |
| Employees: | 268 | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Rocket Pharmaceuticals Inc. Warrant News
RCKTW Breaking Stock News: Dive into RCKTW Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating
MT Newswires
2 days ago
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise
Business Wire
2 days ago
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Zacks
5 days ago
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Associated Press Finance
5 days ago
Rocket Pharmaceuticals: Q1 Earnings Snapshot
Business Wire
5 days ago
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Zacks
12 days ago
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
Insider Monkey
18 days ago